Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Alirocumab in Patients With Primary Hypercholesterolemia Not Treated With a Statin
Brief Summary: Primary Objective:

To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by a regimen of Alirocumab including a starting dose of 150 mg every 4 weeks (Q4W) as add-on to non-statin lipid modifying background therapy or as monotherapy in comparison with placebo in participants with primary hypercholesterolemia not treated with a statin.

Secondary Objective:

* To evaluate the effects on other lipid parameters of Alirocumab 150 mg Q4W versus placebo.
* To evaluate the safety and tolerability of Alirocumab 150 mg Q4W.

Alirocumab 75 mg Q2W was added as a calibrator arm.


Options:
A: Arm Label: Placebo Q2W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Alirocumab, Drug: Placebo (for Alirocumab), Drug: Non-statin LMT, Other: Diet Alone | Arm Label: Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator); Type: OTHER; Interventions: Drug: Alirocumab, Drug: Non-statin LMT, Other: Diet Alone | Arm Label: Alirocumab 150 mg Q4W/Up to 150 mg Q2W; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Placebo (for Alirocumab), Drug: Non-statin LMT, Other: Diet Alone | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 150 mg Q4W/Up to 150 mg Q2W, Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator), Placebo Q2W | Intervention Type: DRUG; Name: Placebo (for Alirocumab); Assigned to Arm(s): Alirocumab 150 mg Q4W/Up to 150 mg Q2W, Placebo Q2W | Intervention Type: DRUG; Name: Non-statin LMT; Assigned to Arm(s): Alirocumab 150 mg Q4W/Up to 150 mg Q2W, Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator), Placebo Q2W | Intervention Type: OTHER; Name: Diet Alone; Assigned to Arm(s): Alirocumab 150 mg Q4W/Up to 150 mg Q2W, Alirocumab 75 mg Q2W/Up to 150 mg Q2W (Calibrator), Placebo Q2W
B: Arm Label: Placebo Q2W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (for Alirocumab), Drug: Lipid-Modifying Therapy (LMT) | Arm Label: Alirocumab 75 mg Q2W/Up to 150 mg Q2W; Type: PLACEBO_COMPARATOR; Interventions: Drug: Alirocumab, Drug: Lipid-Modifying Therapy (LMT) | Intervention Type: DRUG; Name: Placebo (for Alirocumab); Assigned to Arm(s): Placebo Q2W | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 mg Q2W/Up to 150 mg Q2W | Intervention Type: DRUG; Name: Lipid-Modifying Therapy (LMT); Assigned to Arm(s): Alirocumab 75 mg Q2W/Up to 150 mg Q2W, Placebo Q2W
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Evolocumab; Type: EXPERIMENTAL; Interventions: Biological: Evolocumab | Intervention Type: BIOLOGICAL; Name: Evolocumab; Assigned to Arm(s): Evolocumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Rosuvastatin 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin, Drug: Placebo | Arm Label: Ezetimibe 10 mg + Rosuvastatin 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin, Drug: Ezetimibe, Drug: Placebo | Arm Label: Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Rosuvastatin, Drug: Placebo | Arm Label: Rosuvastatin 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin, Drug: Placebo | Arm Label: Ezetimibe 10 mg + Rosuvastatin 20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rosuvastatin, Drug: Ezetimibe, Drug: Placebo | Arm Label: Alirocumab 75 mg/ up to 150 mg + Rosuvastatin 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Alirocumab, Drug: Rosuvastatin, Drug: Placebo | Intervention Type: DRUG; Name: Alirocumab; Assigned to Arm(s): Alirocumab 75 mg/ up to 150 mg + Rosuvastatin 20 mg, Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg | Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): Alirocumab 75 mg/ up to 150 mg + Rosuvastatin 20 mg, Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg, Ezetimibe 10 mg + Rosuvastatin 10 mg, Ezetimibe 10 mg + Rosuvastatin 20 mg, Rosuvastatin 20 mg, Rosuvastatin 40 mg | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): Ezetimibe 10 mg + Rosuvastatin 10 mg, Ezetimibe 10 mg + Rosuvastatin 20 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Alirocumab 75 mg/ up to 150 mg + Rosuvastatin 20 mg, Alirocumab 75 mg/up to 150 mg + Rosuvastatin 10 mg, Ezetimibe 10 mg + Rosuvastatin 10 mg, Ezetimibe 10 mg + Rosuvastatin 20 mg, Rosuvastatin 20 mg, Rosuvastatin 40 mg

Answer: A